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Abstract (Max 250 words) 81 
 82 
An unmet need remains for a bone graft substitute material that is 83 
biocompatible, biodegradable and capable of promoting osteogenesis 84 
safely in vivo. The aim of this study was to investigate the use of a 85 
novel collagen-hydroxyapatite (CHA) bone graft substitute in the 86 
clinical treatment of a mandibular bone cyst in a young horse and to 87 
assess its potential to enhance repair of the affected bone. A 2 year 88 
old Thoroughbred filly, presenting with a multilobulated aneurysmal 89 
bone cyst was treated using the CHA scaffold. Post-operative clinical 90 
follow-up was carried out at 2 weeks and 3, 6 and 14 months. 91 
Cortical thickening in the affected area was observed from CT 92 
examination as early as 3 months post-surgery. At 14 months, 93 
reduced enlargement of the operated mandible was observed, with no 94 
fluid filled area. The expansile cavity was occupied by moderately 95 
dense mineralised tissue and fat and the compact bone was 96 
remodelled, with a clearer definition between cortex and medulla 97 
observed. This report demonstrates the successful application of the 98 
CHA scaffold material in the promotion of enhanced bone repair in 99 
this craniomaxillofacial indication and thus the potential of this 100 
material for translation to human applications. 101 
102 
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1. Introduction 103 
Segmental bone defects, occurring as a result of fractures, tumours, 104 
bone cysts and other diseases, remain a significant challenge for 105 
orthopaedic surgeons. Currently, the “gold standard” clinical approach 106 
involves the surgical harvesting of autograft tissue, taken from the 107 
patient's own body and subsequently re-implanted into the defect 108 
site. However, due to the limitations associated with autograft tissue, 109 
particularly in the treatment of large area defects, alternative 110 
solutions are required. While tissue-derived substitutes such as 111 
allografts and xenografts can offer practical advantages over 112 
autograft material (e.g. no need for additional surgery, “off the shelf” 113 
availability, size of graft material), their use is limited due to concerns 114 
over immune reactions and transfer of host diseases.  115 
 116 
Focus has now moved to the development of bone graft substitutes 117 
and tissue engineered biomaterial scaffolds. Numerous materials are 118 
currently under development, with investigators working to optimise 119 
scaffold properties including biocompatibility, osteoinductivity, 120 
osteoconductivity, mechanical resilience, and functional resorption 121 
while minimizing inflammation and foreign body reaction (Szpalski et 122 
al., 2012). More recently, there has recently been a move towards 123 
the incorporation of cells, growth factors and cellular signalling 124 
molecules into these scaffold materials. In particular, the use of 125 
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growth factors for stimulating bone repair in challenging surgical 126 
cases has become popular since the identification of bone 127 
morphogenetic protein-2 (BMP-2) as an important growth factor in 128 
bone formation. Recombinant versions (rhBMP-2 Infuse, Medtronic, 129 
Inc (FDA, 2002) and rhBMP-7, (OP-1, Novo Noradisk (FDA, 2001)) 130 
have received FDA approval for specified surgical procedures, but 131 
initially successful results (Sciadini and Johnson 2000; Yasko et al., 132 
1992) and subsequent human trials (Boden et al., 2000; McKay et 133 
al., 2002) have been called into question by numerous studies citing 134 
safety concerns (Garrett et al., 2010; Shields et al., 2006; Vaidya et 135 
al., 2009; Wong et al., 2008). In addition, such is the need for a 136 
viable alternative to autogenous bone that up to 85% of reported 137 
BMP-2 use was off-label (Services DoHaH, 2010), thus leading to the 138 
US Department of Health and Human Services calling for a review of 139 
current evidence on the safety of rhBMP-2 doses and applications 140 
(Services DoHaH, 2010). While this is concerning for orthopaedic 141 
surgeons, it simply means that there is still an enduring and unmet 142 
need for a bioactive, load-bearing tissue-engineering scaffold, which 143 
is biocompatible, biodegradable and capable of facilitating and 144 
promoting significant osteogenesis safely when implanted in vivo.  145 
 146 
Research in the Tissue Engineering Research Group (TERG) in the 147 
Royal College of Surgeons in Ireland, has led to the development of a 148 
8 
 
biocompatible, biomimetic and highly porous (> 95%) collagen 149 
hydroxyapatite (CHA) composite scaffold (Gleeson et al., 2010). The 150 
CHA scaffold is fabricated by incorporating a ceramic hydroxyapatite 151 
particle phase into a collagen-based scaffold using a patented mixing 152 
process (O’Brien et al., 2007) to produce a highly porous scaffold 153 
with a composition optimised for bone repair. The osteoconductive 154 
properties of the scaffold have been demonstrated in vitro (Gleeson 155 
et al., 2010). Regenerative potential has been demonstrated in vivo 156 
in a rat calvarial defect (Gleeson et al., 2010) and in load bearing 157 
rabbit radial model (Lyons et al., 2014). Significantly, the CHA 158 
scaffold demonstrated comparable results to a collagen GAG (CG) 159 
scaffold loaded with BMP2 (Lyons et al., 2014). Further analysis has 160 
demonstrated that the positive healing response is due to the innate 161 
osteoinductivity of the scaffold as a result of the method of 162 
incorporation and presentation of HA within it (Murphy et al., 2014). 163 
 164 
This study describes the use of this novel CHA bone graft substitute 165 
as a viable alternative to autogenous bone in the treatment of an 166 
aneurismal bone cyst in the mandible of a 2 year old Thoroughbred 167 
filly. Aneurysmal bone cysts (ABCs) are rare bone lesions that can 168 
affect the axial and appendicular skeleton of young animals. The 169 
mandible is the most common location for ABCs in horse. In humans, 170 
the metaphysis of long bones, pelvis, and vertebral column are the 171 
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most commonly affected areas (Cottalorda et al., 2004). There is 172 
currently little consensus regarding treatment options for such bone 173 
lesions and their ultimate effectiveness. Curettage is commonly 174 
performed and is sufficient for inactive lesions. However, the extent 175 
of mandibular cortical thinning in this case raised significant concerns 176 
about the use of curettage and long-term stabilisation of the tissue 177 
through normal bone remodelling processes with pathological fracture 178 
of the mandible posing a significant risk to the patient (Ordidge et al., 179 
2001). The aim of this study was to thus investigate the use of the 180 
CHA bone graft substitute in this craniomaxillofacial indication and to 181 
assess its potential to promote osteogenesis and cortical thickening of 182 
the affected mandibular compact bone. 183 
184 
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2. Materials and Methods 185 
2.1 Case Description 186 
A 2 year old Thoroughbred filly presented to University College Dublin 187 
Veterinary Hospital with a large firm swelling of the right mandible of 188 
unknown duration. The whole horizontal mandibular ramus was 189 
enlarged, filling almost the entire intermandibular space (Fig. 1A). 190 
Although no overt pain was noted under palpation, the area was 191 
warm to the touch and the filly anticipated palpation. She was 192 
observed to drink, eat and chew hay, her body condition was 2/5 193 
(Carroll et al., 1988). Routine haematology and serum biochemistry 194 
were carried out and were unremarkable.  195 
 196 
Radiography of the right mandible revealed a multiloculated 197 
radiolucent expansible lesion with “soap bubble appearance” 198 
extending from the mental foramen to the rostral root of the second 199 
molar (M2; Triadan 410) (Fig. 1B). The compact bone was ventrally 200 
thinner than normal but no periosteal reaction was noted. 201 
Misalignment and distortion of the permanent teeth was noted, as 202 
well as a suspicion of lysis of the 4th premolar (PM4; Triadan 408) 203 
tooth bud. Computed tomography (CT) revealed a fluid (Hounsfield 204 
unit (HU) 20) expansible mass in the horizontal ramus of the right 205 
mandible (Fig. 1D). The expansile mass extended from the right 206 
mental foramen to right mandibular M3 (Triadan 411) tooth bud (Fig. 207 
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1C). The mandible measured 5.5 cm at its maximal width (left 208 
mandible at the same level 2.5 cm for comparison) and the mass 209 
occupied 3/4 of the height of the mandible. The right mandibular 210 
compact bone was thinner than normal (1-3 mm compared to 1.3-4.8 211 
mm on the left mandible at the same level). It was also noted that in 212 
some focal areas the cortex was perforated and the right mental 213 
foramen was enlarged. The permanent teeth were distorted (mainly 214 
PM3 (Triadan 407)) and/or displaced by the mass. Hypoplasia of the 215 
bud of PM4 (Triadan 408) was also noted. Intraoperative aspiration of 216 
the cystic fluid was performed and cytology revealed a non-septic 217 
inflammation (TP=54 g/L, WBC=0.16 x109/L, mainly macrophages) 218 
with mild past and recent haemorrhage and mild benign osteoclast 219 
proliferation. A presumptive diagnosis of a multilobulated mandibular 220 
bone cyst with tooth displacement, distortion and hypoplasia was 221 
made.  222 
 223 
2.2 Scaffold Fabrication 224 
CHA scaffolds were fabricated using a previously described freeze-225 
drying technique. Briefly, Type 1 collagen (Collagen Matrix Inc., NJ, 226 
USA), hydroxyapatite ((Captal ‘R’ Reactor Powder, Plasma Biotal, UK) 227 
and a 0.5M acetic acid solution were combined using a patented 228 
blending protocol [13, 14]. The resultant CHA suspension was 229 
pipetted into stainless-steel trays (internal dimensions - 60mm x 230 
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60mm; 18ml CHA solution per tray) and freeze-dried (Virtis Genesis 231 
25EL, Biopharma, Winchester, UK) at a constant cooling rate of 1 232 
°C/min to a final freezing temperature of -40°C ((Gleeson et al., 233 
2010; O’Brien et al., 2007). Following freeze-drying, dehydrothermal 234 
(DHT) treatment was carried out at a temperature of 105C under a 235 
vacuum of 0.05 bar for 24 hours (Vacucell 22; MMM, Germany). 236 
Scaffolds were then chemically cross-linked for 2 hours at room 237 
temperature with 1-ethyl-3-3-dimethyl aminopropyl carbodiimide 238 
(EDAC)/ N-Hydroxysuccinimide (NHS) (Sigma-Aldrich, Arklow, 239 
Ireland) at a concentration of 6 mM EDAC per gram of collagen and a 240 
5:2 molar ratio of EDAC:NHS (Gleeson et al., 2010).  241 
 242 
2.3 Surgical Procedure 243 
The mare was anesthetised and positioned in dorsal recumbency. A 244 
ventromedial approach to the enlarged horizontal ramus was 245 
performed via a 20 cm long skin incision. The poorly adherent 246 
periosteum was reflected and the ventral surface of the bone 247 
examined. Black discolorations spots were visible on the compact 248 
bone surface. Two osteal windows (8 x 3 cm and 6 x 3 cm) separated 249 
by a 2 cm wide bridge were created using an oscillating saw to give 250 
access to the multilobulated cyst (Fig. 2B). A yellow 251 
serohaemorrhagic fluid was aspirated from one of the cysts (Fig. 2A). 252 
Suction was used to aspirate the remaining cystic fluid. The cyst 253 
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lining and bone spikes adherent to the dorsal aspect of the bone flaps 254 
were curetted and flushed (Fig. 2C). Six 2 mm holes were drilled in 255 
the corner/edge of the flaps and parent bone to enable flap re-256 
apposition at the end of surgery. The flaps were preserved in swabs 257 
impregnated with saline and autologous venous blood and disposed in 258 
a sterile kidney dish.  259 
 260 
Several connected cystic structures were visible within the mandible 261 
cavity (Fig. 2B). With assistance from the CT images, the cystic cavity 262 
was debrided using a curette. The mandibular nerve was identified 263 
and the debridement and curettage was initiated rostral to PM2 264 
(Triadan 406). Any cystic and abnormal bone material was removed. 265 
The bud of PM2 was difficult to differentiate from the cystic tissue and 266 
was also debrided to remove any suspicious material. The 267 
debridement was then continued around PM3 (407), PM4 (408), M1 268 
(409) and M2 (410). The cavity volume was estimated by filling with 269 
saline and found to be 240-250 ml in volume (Fig. 2C). The cavity 270 
was then washed with saline twice and all the fluid suctioned. 271 
 272 
As a risk of traumatic/pathologic fracture was considered high on this 273 
case, CHA scaffold sheets, measuring 5 x 60 x 60 mm in dimension 274 
were placed into the defect site to encourage rapid bone healing. The 275 
scaffolds were positioned along the internal walls of the mandible 276 
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with 5 sheets inserted in total. Two CHA sheets were inserted (flat) 277 
on the medial side, one (flat) on the lateral side, one caudally (rolled) 278 
and one rostrally (rolled) in the cavity (Fig. 2D). The bone flaps were 279 
sutured in place to the parent bone using USP 2-0 polydioxanone 280 
suture material passed through drilled holes. The surface of the bone 281 
was then flushed with gentamicin (500 mg) and the periosteum 282 
sutured with polyglecaprone USP 2-0. A gentamicin (500mg) flush 283 
was repeated and the skin apposed using skin staples and a 284 
protective bandage was placed for recovery. Using a rope-assisted 285 
recovery system the mare recovered from anaesthesia uneventfully. 286 
 287 
2.4 Post-operative Assessment 288 
Post-operative clinical re-evaluation was performed at 2 weeks and 3, 289 
6 and 14 months. CT examinations were performed at 3 and 14 290 
months post surgery. In order to evaluate the remodelling of the right 291 
mandible following treatment, mandible bone thickness, and 292 
mandible cavity area and volume measurements were carried out 293 
using the OsiriX HD 4.0 software (Pixmio, Geneva, Switzerland). 294 
Measurements at each time point are reported as a % size difference 295 
relative to the left mandible (normal), thus accounting for any normal 296 
anatomical changes resulting from growth of the animal during the 297 
study. The cavity area measurements in each case were compared at 298 
the widest point of the mandible. 299 
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 300 
3. Results 301 
3.1 Histopathology Results 302 
Tissue samples (cystic material and material coming from PM2 (406)) 303 
harvested during surgery were sent for histopathology (Fig. 3A). The 304 
features of these samples were consistent with a multiloculated 305 
aneurysmal bone cyst. The dental material submitted was consistent 306 
with normal tooth root material. 307 
 308 
3.2 Post-operative Outcome 309 
Post-operative evaluation at 2 weeks revealed a fully healed surgical 310 
wound. At 3 months post-surgery, the operated mandible appeared 311 
subjectively less enlarged and the oral examination was within 312 
normal limits. A CT examination revealed that most of the expansile 313 
cavity was filled by moderately dense mineralised tissue (HU 200-314 
300), with a few remaining fluid filled areas (HU 10) still apparent 315 
(Fig. 3C). The right mandible measured 5.6 cm at its maximal width 316 
(left mandible 2.4 cm). The compact bone was continuous and was 317 
generally thicker than previously described (1.2-10.7 mm compared 318 
to 1.9-7.2 mm at the same levels on the left mandible). Most of the 319 
tooth buds surrounding the cyst had grown but were still smaller 320 
compared to the opposite side. Their displacement and distortion was 321 
less severe than pre-surgery. The right mandibular PM2 tooth bud 322 
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showed signs of resorption of its roots. The area at the widest point 323 
of the mandible was reduced compared to pre-operative 324 
measurements, although the volume was slightly increased, most 325 
likely due to growth of the animal (Fig. 4). 326 
 327 
At 6 months post-surgery the horse was in training and no problems 328 
with her jaw, masticatory function or bite acceptance were recorded. 329 
At 14 months post-surgery, the operated mandible appeared 330 
subjectively less enlarged than at 3 months. A non-painful bony 331 
prominence was noted on the ventral-lateral-rostral aspect of the 332 
right mandible. On oral examination the decidual PM3 (Triadan 807) 333 
on the right mandible was missing while it was still firmly attached on 334 
the left mandibular arcade. Eruption of the permanent PM3 (Triadan 335 
407) could be palpated in the gap between PM2 (Triadan 406) and 336 
PM4 (408). A repeat CT examination revealed the right mandible 337 
measured 4.5 cm at its maximal width (left mandible 2.7 cm). There 338 
was no fluid filled area and the expansile cavity was occupied by 339 
moderately dense mineralised tissue (HU 150-300) and fat (HU 20-340 
100) (Fig. 5). The compact bone of the right mandible was 341 
remodelled and a clearer definition between cortex and medulla was 342 
noted. The cortex was thinner than at 3 months post-surgery (1-2.4 343 
mm compared to 0.7-4.7 mm at the same levels on the left 344 
mandible). The cavity area and volume measurements showed the 345 
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right mandible to be less enlarged than prior to surgery (Fig. 4). On 346 
the right side PM2 (Triadan 406) appeared to have erupted correctly 347 
but this tooth was significantly shorter than 306 (3.2 cm versus 7.4 348 
cm). PM3 (Triadan 407) seemed to have just erupted. This tooth was 349 
still slightly distorted with its root pointing laterally, deforming the 350 
right mandible externally. Both PM4 (Triadan 408 and 308) presented 351 
the same length and were covered by their dental caps. The molars 352 
were symmetric between left and right and normal in appearance. 353 
 354 
4. Discussion 355 
The study demonstrates the successful clinical use of a collagen-356 
hydroxyapatite bone graft substitute for the treatment of an equine 357 
craniomaxillofacial bone cyst. The CHA scaffold applied in this case 358 
has been designed to address a major unmet need, for a bone graft 359 
substitute material that is biocompatible, biodegradable and capable 360 
of promoting osteogenesis safely in vivo. Follow-up at 3 and 14 361 
months post-implantation revealed reduced enlargement of the 362 
operated mandible, initial thickening of the compact bone with no 363 
fluid filled area, and later remodelling of the compact bone with a 364 
clearer definition between cortex and medulla. The results show the 365 
potential of the scaffold to promote osteogenesis and cortical 366 
thickening of the affected mandibular compact bone.  367 
 368 
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An aneurysmal bone cyst is a reasonably rare condition occurring in 369 
animals (Thompson et al., 2007; Bryant et al., 2012) and humans 370 
(Cottalorda et al., 2004). Many hypotheses have been proposed to 371 
explain the etiology and pathogenesis of aneurysmal bone cysts 372 
(Jaffe et al., 1942; Lichtenstein et al., 1957). One of the more 373 
commonly accepted ideas that increased venous pressure and a 374 
resultant dilation and rupture of the local vascular network could 375 
trigger onset of the cystic growth (Jaffe et al., 1942). The lesion may 376 
be primary with possible genetic predisposition (Leithner et al., 377 
2004), or secondary to a pre-existing lesion such as fibrous dysplasia, 378 
hematoma from trauma, bleeding disorders, or within a pre-existing 379 
bone tumor (Leithner et al., 2004). Giant cell tumors are the most 380 
common cause in humans (Wu et al., 2011). In the case of the 381 
presenting filly, no bleeding disorder was identified pre-operatively 382 
and no bone tumor was observed on histopathological analysis. No 383 
previous trauma was reported although this could not be totally 384 
excluded as her early history was undocumented. The potential 385 
genetic predisposition of her family to bone lesions was not 386 
investigated. The etiology of this lesion remains unclear in this 387 
patient. 388 
 389 
Absolute alcohol intracystic injection has been reported to be 390 
successful in the management of aneurysmal bone cysts in humans 391 
19 
 
(Cottalorda et al., 2004). However, due to the multiloculated 392 
appearance of the cyst, the proximity of the tooth roots/buds and 393 
mandibular nerve, this non-invasive option was considered too risky. 394 
Autologous cancellous bone grafting was also considered a poor 395 
option due to the size of the cavity. The use of a synthetic bone graft 396 
thus provided an ideal solution. The technique employed in this case 397 
involved surgical curettage to remove the cyst followed by 398 
implantation of a tissue engineered scaffold to encourage repair of 399 
the mandible bone. This is the first time that this combination of 400 
techniques has been used to treat a large aneurysmal bone cyst. Due 401 
to the high risk of traumatic or pathologic mandibular fracture in this 402 
case, during surgery particular attention was paid to apply the 403 
scaffold to the area where the compact bone was extremely thin or 404 
perforated. Two additional sheets of the CHA bone graft substitute 405 
were also rolled and placed cranially and caudally to provide some 406 
healing in the cavity itself and underneath the bone flaps. The CHA 407 
scaffold displayed a perfect ability to adhere to the compact bone and 408 
demonstrated sufficient mechanical strength, flexibility and durability 409 
to withstand surgical handling and to be rolled and shaped to fit into 410 
the required spaces within the mandible cavity. The bone fenestration 411 
technique with the central bridge provided stability of this weakened 412 
mandibular bone during the curettage and early post-operative 413 
period. Although the blood supply to the bone flaps was completely 414 
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absent for the first days after surgery, no bone necrosis was noted 415 
and proper healing was evident on CT examination performed 3 416 
months post-surgery. This maximum bone preservation approach 417 
likely contributed to the good recovery of this mare. 418 
 419 
Bone repair was quantified at 3 months and 14 months post-surgery. 420 
The amount and quality of compact bone produced in 3 months was 421 
considered exceptional on comparative CT examinations. Analysis of 422 
the CT images revealed no trace of the CHA scaffold thus 423 
demonstrating the biodegradability of the scaffold and its successful 424 
resorption by the body as new repair tissue is formed. Prior to 425 
surgery, growth of the tumor within the mandible led to enlargement 426 
of mandible and thinning of the mandibular compact bone leaving the 427 
horse at significant risk of pathological facture. Evaluation at 3 428 
months confirmed that rapid repair of the mandible bone had 429 
occurred. Importantly, the compact bone was found to be continuous, 430 
with increased thickness compared to pre-surgery values and thus 431 
the risk of pathological fracture of the mandible was significantly 432 
reduced.  433 
 434 
At 14 months, CT analysis revealed that further remodelling of the 435 
compact bone of the right mandible had occurred and a clearer 436 
definition between cortex and medulla was noted. This was confirmed 437 
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through mandible volume and area measurements, with the cavity 438 
volume being significantly reduced at 14 months compared to pre- 439 
surgery values. Importantly, no reoccurrence of the cyst was 440 
observed up to 14 months post-surgery. Oral examination revealed 441 
that on the right side, PM2 was significantly shorter than the left. It is 442 
likely the dental bud of PM2 was damaged during the curettage of the 443 
most rostral part of the cavity. Although curettage was carried out 444 
carefully with the use of a narrow suction tip to remove the fibrous 445 
tissue lining cystic material can be easily confounded with dental buds 446 
during surgery. While PM2 will require further monitoring it is unlikely 447 
to cause any significant issues.  448 
 449 
These results demonstrate the benefits of the osteoinductive 450 
properties provided by the hydroxyapatite component of the scaffold 451 
combined with the biocompatibility and rapid degradation associated 452 
with the collagen component of the CHA scaffold. Notably, the bone 453 
remodelling observed here was achieved in the absence of additional 454 
osteogenic factors confirming the previously demonstrated 455 
osteoconductive and osteoinductive properties of this CHA scaffold 456 
and its ability to lead to tissue regeneration without the requirement 457 
for addition of growth factors such as BMP (Gleeson et al., 2010; 458 
Lyons et al., 2014; Murphy et al., 2014). This off-the-shelf, cell-free 459 
approach overcomes many of the limitations associated with currently 460 
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used autologous bone grafting procedures providing an ideal 461 
alternative from a clinical and regulatory stand-point.  462 
 463 
5. Conclusion 464 
This case study investigated the use of the CHA scaffold in the 465 
treatment of a multilobulated aneurysmal bone in a young horse and 466 
demonstrated its potential to enhance repair of the affected bone. 467 
Clinical follow-up at 3 and 14 months post-implantation revealed 468 
reduced enlargement of the operated mandible, initial thickening of 469 
the compact bone with no fluid filled area, and later remodelling of 470 
the compact bone with a clearer definition between cortex and 471 
medulla. Overall, the successful clinical outcome and enhanced bone 472 
formation observed in this craniomaxillofacial indication demonstrates 473 
the potential of this bone graft substitute for use in this and other 474 
equine indications and also for translation to human applications.  475 
 476 
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